PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23790173-7 2013 Patients with low mRNA expression of ERCC1 or TYMS preferred higher DCR to cisplatin and pemetrexed than those with high expression (P = 0.39 and P= 0.11). Pemetrexed 89-99 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 37-42 27502726-5 2016 RESULTS: The best-validated predictive biomarkers for efficacy are currently ERCC1, RRM1, and TS for platinum agents, gemcitabine and pemetrexed, respectively. Pemetrexed 134-144 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 77-82 27893326-13 2017 Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99; 95% CI, 0.73 to 1.33; interaction P = .64). Pemetrexed 72-82 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 95-100 27893326-13 2017 Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99; 95% CI, 0.73 to 1.33; interaction P = .64). Pemetrexed 72-82 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 95-100 27893326-13 2017 Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99; 95% CI, 0.73 to 1.33; interaction P = .64). Pemetrexed 72-82 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 95-100 21262916-0 2011 Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Pemetrexed 139-149 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 25-68 21262916-3 2011 This retrospective study aimed to assess the role of excision repair cross-complementing group-1 (ERCC1) and thymidylate synthase (TS) in tumors, and correlate expression levels and polymorphisms of these key determinants of drug activity with the outcome of MPM patients treated with carboplatin/pemetrexed in first-line setting. Pemetrexed 297-307 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 98-103 31479512-7 2020 Based on concurrent biomarker expression, combinations of immunotherapy with platinum (ERCC1 negativity) or with doxorubicin, epirubicin, or etoposide (TOP2A positivity), have a higher probability of response while combinations with irinotecan or topotecan (TOPO1 positivity), with gemcitabine (RRM1 negativity), and fluorouracil, pemetrexed, or capecitabine (TS negativity) may be of less benefit. Pemetrexed 331-341 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 87-92 29572009-9 2018 CONCLUSION: A combination of ERCC1 and ERCC2 polymorphisms may predict OS among pemetrexed/platinum treated advanced non-squamous NSCLC patients. Pemetrexed 80-90 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 29-34 23912706-0 2013 Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells. Pemetrexed 0-10 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 25-30 25028118-0 2014 Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. Pemetrexed 92-102 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 31-36 25028118-1 2014 PURPOSE: We presented retrospective analysis of up to five polymorphisms in TS, MTHFR and ERCC1 genes as molecular predictive markers for homogeneous Caucasian, non-squamous NSCLC patients treated with pemetrexed and platinum front-line chemotherapy. Pemetrexed 202-212 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 90-95 25246386-0 2014 Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients. Pemetrexed 109-119 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 35-40 25246386-4 2014 The aim of this retrospective multicenter study was to assess the correlation between TS, 5,10-methylenetetrahydrofolate reductase (MTHFR) and excision repair cross-complementing group 1 (ERCC1) gene polymorphisms and the efficacy of pemetrexed-based first-line chemotherapy of mesothelioma patients. Pemetrexed 234-244 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 143-186 25246386-4 2014 The aim of this retrospective multicenter study was to assess the correlation between TS, 5,10-methylenetetrahydrofolate reductase (MTHFR) and excision repair cross-complementing group 1 (ERCC1) gene polymorphisms and the efficacy of pemetrexed-based first-line chemotherapy of mesothelioma patients. Pemetrexed 234-244 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 188-193 23912706-8 2013 Combining resveratrol with pemetrexed resulted in a synergistic cytotoxic effect, accompanied with the reduction of phospho-p38 MAPK and ERCC1 protein levels, and a DNA repair capacity. Pemetrexed 27-37 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 137-142 23912706-10 2013 In this study, for the first time, we have demonstrated the synergistic effect of combined treatment with resveratrol and pemetrexed in human NSCLC cells through downregulation of the MKK3/6-p38 MAPK-ERCC1 signal, suggesting a potential benefit of combining resveratrol and pemetrexed to treat lung cancer in the future. Pemetrexed 122-132 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 200-205 23523421-0 2013 Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Pemetrexed 108-118 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 25-30 23523421-11 2013 Protein expressions of TS and ERCC1 were associated with clinical outcomes in patients with pulmonary adenocarcinoma who were treated with pemetrexed/cisplatin as first-line chemotherapy. Pemetrexed 139-149 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 30-35 23482788-8 2013 For patients with high expression of ERCC1 and tubulin, uracil-tegafur, pemetrexed, and gemcitabine may be the alternative agents for personalized chemotherapy. Pemetrexed 72-82 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 37-42